Expertise in
5
conditions

Christine Mauz-Korholz

Ernst Grube Str. 40, 
Halle, NI, DE 
Expertise in
5
conditions
Ernst Grube Str. 40, 
Halle, NI, DE 

Overview

Christine Mauz-Korholz practices practicing medicine in Halle, Germany.

Ms. Mauz-Korholz is highly rated in 5 conditions, according to our data. Her clinical expertise encompasses Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL), Infantile Neutropenia, and Bone Marrow Transplant.

She is actively involved in clinical research, co-authoring 87 peer reviewed articles and participating in 1 clinical trial.

Gender

Female

Locations

Ernst Grube Str. 40, Halle, NI 06120, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy, or Who Have the T315I Mutation
A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy, or Who Have the T315I Mutation
Enrollment Status: Terminated
Publish Date: October 02, 2025
Intervention Type: Drug
Study Drug: Ponatinib
Study Phase: Phase 1/Phase 2

87 Total Publications

Omitting Bone Marrow Sampling in FDG-Avid Rhabdomyosarcoma With 2-[18F]FDG PET-Negative Marrow: Results From an International Retrospective Study.
Omitting Bone Marrow Sampling in FDG-Avid Rhabdomyosarcoma With 2-[18F]FDG PET-Negative Marrow: Results From an International Retrospective Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 24, 2026

Frequently Asked Questions about Christine Mauz-Korholz

Is Christine Mauz-Korholz a top-rated expert for Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Christine Mauz-Korholz is classified as an Elite expert for Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Christine Mauz-Korholz participate in research or clinical trials?

Yes. Christine Mauz-Korholz has published 87 articles and abstracts on conditions like Hodgkin Lymphoma. You can view a list of Christine Mauz-Korholz's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Mauz-Korholz's expertise for a condition
ConditionClose
    View All 8 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile